Genetic Testing Report
: Analysis on the Market, Trends, and TechnologiesThe global genetic testing market reached an estimated USD 22.74 billion in 2024 and is projected to surpass USD 73.99 billion by 2037 at a CAGR of over 9.5% from 2025 to 2037 (Genetic Testing Market Size & Share | Growth Report 2037). The internal trend analysis identifies 3,359 companies actively working on genetic testing, reflecting a mature yet expanding ecosystem. Demand is driven by rising hereditary and rare disease prevalence, advances in next-generation sequencing and AI-enabled diagnostics, and growing adoption of prenatal, pharmacogenomic, and direct-to-consumer testing.
We updated this report 56 days ago. Missing information? Contact us to add your insights.
Topic Dominance Index of Genetic Testing
The Topic Dominance Index combines the distribution of news articles that mention Genetic Testing, the timeline of newly founded companies working within this sector, and the share of voice within the global search data
Key Activities and Applications
- Mutation Detection and Analysis: Methods to identify single-nucleotide polymorphisms and other genetic variants form the foundation of diagnostics.
- Disease Diagnosis and Risk Assessment: Tests for multifactorial and inherited disorders enable early identification of predispositions to conditions like cystic fibrosis and neurodegenerative diseases.
- Personalized Medicine and Pharmacogenomics: Pharmacogenomic assays guide drug selection and dosing, reducing adverse reactions and improving outcomes; genetic testing can help prevent ADRs.
- Non-invasive Prenatal Testing (NIPT): Cell-free fetal DNA assays enable early fetal screening without invasive procedures.
- Direct-to-Consumer (DTC) Testing: At-home kits provide ancestry and health-risk insights without physician involvement (Direct-to-Consumer Genetic Testing Market Landscape).
Emergent Trends and Core Insights
- Rising Genetic Disease Burden: An estimated 72–80% of rare diseases are genetically driven, intensifying demand for diagnostics.
- AI and Machine Learning Integration: AI-powered platforms are enhancing variant interpretation and predictive accuracy, expanding clinical utility.
- North America’s Market Leadership: North America held 54% of global revenue in 2024, propelled by high consumer awareness, self-testing kit availability, and healthcare investment (Genetic Testing Market Size To Hit USD 65.03 Bn By 2034).
- Liquid Biopsy Adoption: Blood-based assays for early cancer detection and prenatal screening captured nearly half of market revenue in 2024.
- Health Equity Focus: Initiatives to optimize test panels for underrepresented populations aim to reduce disparities in genomic healthcare.
Technologies and Methodologies
- Next-Generation Sequencing (NGS): The leading technology with ~49.3% revenue share in 2024, projected for continued dominance.
- High-Throughput Sequencing: Enables large-scale rare disease screening, identifying 25% more risks compared to targeted panels (High-throughput sequencing genetic testing identifies 25% more rare disease risks).
- PCR-Based Testing: Widely used for targeted mutation analysis and rapid diagnostics (Global Genetic Testing Market By Product).
- Polygenic Risk Scores (PRS): Aggregates thousands of variants to estimate lifetime disease risk, guiding prevention strategies (Selection, optimization, and validation of genetic tests for 10 common diseases).
- Microarrays and SNP Arrays: Cost-effective genotyping platforms for ancestry, carrier screening, and CNV analysis (Genetic testing moving into the mainstream).
Genetic Testing Funding
A total of 619 Genetic Testing companies have received funding.
Overall, Genetic Testing companies have raised $40.7B.
Companies within the Genetic Testing domain have secured capital from 2.2K funding rounds.
The chart shows the funding trendline of Genetic Testing companies over the last 5 years
Genetic Testing Companies
- Haplox: Specializes in preimplantation genetic testing solutions to enhance IVF success rates by screening embryos for aneuploidy and monogenic disorders.
- 3billion: Offers AI-driven rare disease diagnostics covering over 20,000 genes with unlimited reanalysis, collaborating with 100 medical centers across 33 countries.
- Berries Health: Develops nutrigenomic supplements and wellness plans based on individual genetic profiles to optimize metabolic health.
- ProbablyGenetic: Utilizes probabilistic models and variant interpretation algorithms to clarify VUS and improve diagnostic yield in complex cases.
- Sequence46: Focuses on targeted sequencing and microbial genomics, delivering customizable panels for infectious disease detection and pathogen surveillance.
Gain a competitive edge with access to 3.5K Genetic Testing companies.
3.5K Genetic Testing Companies
Discover Genetic Testing Companies, their Funding, Manpower, Revenues, Stages, and much more
Genetic Testing Investors
Leverage TrendFeedr’s sophisticated investment intelligence into 2.3K Genetic Testing investors. It covers funding rounds, investor activity, and key financial metrics in Genetic Testing. investors tool is ideal for business strategists and investment experts as it offers crucial insights needed to seize investment opportunities.
2.3K Genetic Testing Investors
Discover Genetic Testing Investors, Funding Rounds, Invested Amounts, and Funding Growth
Genetic Testing News
TrendFeedr’s News feature provides a historical overview and current momentum of Genetic Testing by analyzing 8.7K news articles. This tool allows market analysts and strategists to align with latest market developments.
8.7K Genetic Testing News Articles
Discover Latest Genetic Testing Articles, News Magnitude, Publication Propagation, Yearly Growth, and Strongest Publications
Executive Summary
The genetic testing sector is poised for sustained expansion, underpinned by escalating hereditary disease prevalence, technological advancements in sequencing and AI, and increasing consumer engagement via DTC and prenatal applications. Stakeholders should prioritize integrating machine learning-driven interpretation platforms, expanding NIPT and liquid biopsy capabilities, and addressing health equity through inclusive panel design. As market leadership consolidates around end-to-end genomic platforms, companies that streamline clinical workflows and ensure data security will capture the greatest value in this evolving landscape.
Interested in contributing your expertise on trends and tech? We’d love to hear from you.
